Poseida Therapeutics’ P-BCMA-ALLO1 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for R/R Multiple Myeloma
Shots:
- The US FDA has granted RMAT designation to P-BCMA-ALLO1 for treating r/r multiple myeloma, based on early data from its P-I trial showing favorable efficacy, safety & off-the-shelf patient access
- The P-I/Ib dose-escalation study assesses the safety & efficacy of P-BCMA-ALLO1 to treat patients with r/r multiple myeloma. New data will be highlighted at the IMS 2024, with further updates planned during H2’24 in coordination with Roche (collaborator for P-BCMA-ALLO1)
- P-BCMA-ALLO1 is an allogeneic CAR-T therapy that contains a VH-based binder targeting BCMA and T stem cell (TSCM)-rich composition. Data featured at ASH 2023 suggested its potential as an effective, safe & reliable treatment for MM
Ref: Poseida Therapeutics | Image: Poseida Therapeutics
Related News:- Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
